Tolerance and Pharmacokinetics of TQ-B3233
Study of Tolerance and Pharmacokinetics of TQ-B3233 Capsule, phase I,single arm.
Tumor
DRUG: TQ-B3233
maximum tolerated dose(MTD), 28 Days|dose-limiting toxicity(DLT), 28 Days|Peak Plasma Concentration(Cmax), up to 28 Days|Peak time(Tmax), up to 28 Days|Half life(t1/2), up to 28 Days|Area under the plasma concentration versus time curve (AUC), up to 28 Days
Objective Response Rate (ORR), up to 24 months
The maximum tolerated dose (MTD) of TQ-B3233 \[ Time Frame: 48 weeks \] \[ Designated as safety issue: Yes \]The highest dose at which no more than 33% of the subjects experience a dose-limiting toxicity (DLT) during treatment.

Pharmacokinetics of TQ-B3233 (in whole blood):In the study of single-dose, full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H5/H8/H10/H12/H24/H48/H72（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D0/D1/D2/D8/D15/D22/D28（D means Day）.